Avenacy Announces Launch of Dexmedetomidine Injection, USP in the U.S. Market [Yahoo! Finance]
IQVIA Holdings, Inc. (IQV)
Last iqvia holdings, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
ir.iqvia.com
Company Research
Source: Yahoo! Finance
SCHAUMBURG, Ill., November 18, 2024 BUSINESS WIRE )--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Dexmedetomidine Injection, USP in the United States as a therapeutic generic equivalent for Precedex® as approved by the U.S. Food and Drug Administration. Dexmedetomidine Injection, USP is an alpha2-adrenergic receptor agonist indicated for: Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Dexmedetomidine Injection should be administered by continuous infusion not to exceed 24 hours. Sedation of non-intubated adult patients prior to and/or during surgical and other procedures. Avenacy's Dexmedetomidine Injection, USP is available as 200 mcg (base) per 2 mL (100 mcg (base) per mL) single-dose vials, with 25 vials per carton. In line with Avenacy's mission to champion patient safety and streamline patient care, Dexmedetomidine
Show less
Read more
Impact Snapshot
Event Time:
IQV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IQV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IQV alerts
High impacting IQVIA Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
IQV
News
- IQVIA Holdings Inc. (NYSE: IQV) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- IQVIA Holdings Inc. (NYSE: IQV) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- IQVIA Holdings Inc. (NYSE: IQV) had its "outperform" rating re-affirmed by analysts at Leerink Partners. They now have a $248.00 price target on the stock, down previously from $260.00.MarketBeat
- BGB Group Appoints David Coman as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Functional Service Providers (FSP) Market to Hit USD 30.70 Billion by 2032, with a CAGR of 8.56% | SNS Insider [Yahoo! Finance]Yahoo! Finance
IQV
Earnings
- 10/31/24 - Beat
IQV
Sec Filings
- 11/8/24 - Form 4
- 11/8/24 - Form 4
- 11/8/24 - Form 4
- IQV's page on the SEC website